Lonza and Sanofi Pasteur enter into long term agreement

Published: 24-Jan-2008

Lonza and sanofi pasteur have entered into a strategic partnership in the area of cell culture vaccine production. The two parties have signed a technical service agreement related to the new cell-based influenza vaccine developed by sanofi pasteur.


Lonza and sanofi pasteur have entered into a strategic partnership in the area of cell culture vaccine production. The two parties have signed a technical service agreement related to the new cell-based influenza vaccine developed by sanofi pasteur.

Under the agreement Lonza will provide sanofi pasteur with its expertise in mammalian cell culture operations. Lonza has already demonstrated the production scale potential in a successful bioreactor run of 20,000 litres.

"This agreement is a significant step forward for Lonza in the area of vaccines, demonstrating that we are now able to offer extensive research, process development and manufacturing services based on our microbial and mammalian expertise," said Dr Stephan Kutzer, head of Lonza Biopharmaceuticals.

Relevant companies

You may also like